Editorial Board About Us

Radioimmunoscintigraphy

All articles from this key word are listed below.

Volume 5, Number 2 Meeting Reviews

Advances in Prostate Cancer Treatment

Highlights from the 2nd International Prostate Cancer Congress, St. Thomas, U.S. Virgin Islands

Alan W Partin Matthew B Gretzer

Prostate-specific antigen Nomograms Radiotherapy Hormone-refractory prostate cancer Radioimmunoscintigraphy Androgen blockade

Volume 8, Number 3 Review Articles

The Importance of Pelvic Lymph Node Dissection in Men With Clinically Localized Prostate Cancer

Diagnostic Review

Alan W Partin H Ballentine Carter Mohamad E Allaf

Despite advances in noninvasive staging, pelvic lymph node dissection (PLND) remains the most accurate means of detecting lymph node metastases in men with clinically localized prostate cancer. Nomograms exist that can identify patients at low risk for lymphatic metastases according to preoperative information. In general, it seems reasonable to omit PLND in men with a biopsy Gleason sum of 6 or less and a prostate-specific antigen level of 10 ng/mL or less. Ultimately, however, this decision should be made according to physician and patient preference, considering the low contemporary morbidity associated with PLND. When PLND is performed, studies suggest that an extended dissection maximizes the detection rate of nodal involvement. Retrospective data indicate that an extended dissection might play a therapeutic role in a subset of patients with a limited lymph node burden. However, this might be an artifact of stage migration, and prospective studies are needed to evaluate this further. [Rev Urol. 2006;8(3):112-119]

Prostate cancer Nomograms Radioimmunoscintigraphy Lymphadenectomy Clinical staging Magnetic resonanceimaging Algorithms

Volume 8, Supplement 1 Review Articles

The Emergence of Radioimmunoscintigraphy for Prostate Cancer

Prostate Cancer Imaging

David G McLeod Thomas E Keane Inger L Rosner M Scott Wingo

The ability to label tissue-specific antibodies has long been of interest for improving detection and guidance for therapeutic applications. The most studied target for prostate cancer is the prostate-specific membrane antigen, which is upregulated in prostate cancer, hormone-refractive disease, and prostate cancer metastases. Investigations using radioimmunoscintigraphy with the radiolabeled 7E11 antibody capromab pendetide have significantly improved sensitivity for prostate cancer detection compared with standard cross-sectional imaging, based on tissue confirmation of pathologic results. Over the past 5 years, significantly greater image resolution from improved camera technology and the use of co-registration to fuse functional and anatomic (computerized tomography and magnetic resonance imaging) images have dramatically enhanced prostate cancer localization. Outcomes data from several sources have spurred a resurgence in interest in this imaging modality. [Rev Urol. 2006;8(suppl 1):S20-S28]

Prostate cancer ProstaScint Prostate-specific membrane antigen Radioimmunoscintigraphy Capromab pendetide Image co-registration Lymph node metastasis